Page 16 - டாகேடா மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Esco seeks to incubate, acquire biotech firms in China as part of global ecosystem strategy Xiang Qian (XQ) Lin, CEO of Esco Group Premium Armed with $200 million funding led by Vivo Capital and Novo Holdings last month, Singapore’s Esco Lifesciences is looking at an accelerated expansion in China, creation of an innovation hub in Boston, acquisition of Western technologies and bringing them to the Asian market, as well as pursuing an active M&A strategy. “We are building a global life sciences ecosystem between Singapore, the US and China, with Singapore as the focal nexus,” Esco CEO Lin Xiangqian said in a video interview with DealStreetAsia from Shanghai.

United statesYae foongEsco lifesciencesLin xiangqianTesco groupNovo holdingsVivo capitalLim lay yewLim yae foongCarmine therapeuticsTakeda pharmaceuticalஒன்றுபட்டது மாநிலங்களில்எஸ்கோ ஆயுள் அறிவியல்எஸ்கோ குழுநோவோ ஹோல்டிங்ஸ்விவோ மூலதனம்